Fulgent Genetics Inc
NASDAQ:FLGT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (19.2), the stock would be worth $-199.6 (1 345% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.5 | $16.03 |
0%
|
| Industry Average | 19.2 | $-199.6 |
-1 345%
|
| Country Average | 19.6 | $-203.47 |
-1 369%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
498.2m USD | -1.5 | -8.2 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14.3 | 56.7 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 9.8 | 13.2 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.4 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.9B EUR | 13.7 | 18 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 16.8 | 23.6 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 16 | 21.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 17.3 | 24.8 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 9.8 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -27.4 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 9.9 | 14.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Fulgent Genetics Inc
Glance View
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
